Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.210
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Mark Manfredi |
Contact Details
Address: 645 Summer Street, Suite 101 Boston, Massachusetts 02210 United States | |
| Phone | 857 273 8343 |
| Website | ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development and Treasurer |
| Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy and Communication |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Bob Lally | Senior Vice President of Finance and Operations |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | S-4/A | Filing |
| Mar 18, 2025 | S-4 | Filing |
| Mar 6, 2025 | ARS | Filing |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 425 | Filing |
| Dec 31, 2024 | SCHEDULE 13G | Filing |